Revolution Medicines a new outperform at RBC on RAS(ON) inhibitors for cancers

RBC Capital Markets has initiated Revolution Medicines (RVMD) at outperform, saying that its platform of "RAS(ON)" inhibitors to treat various cancers has demonstrated strong efficacy thus far. The ...
News-Medical.Net on MSN

Studies identify complementary approaches to overcome drug resistance in KRAS G12C–mutant lung cancer

Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C–mutant non-small ...
Becker's Hospital Review

Dana-Farber launches gene therapeutics center

Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers. RAS gene mutations are found in 20% of all ...
News Medical

New discovery reveals how mutant RAS genes drive tumor growth

Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their ...
Science Daily

Researchers uncover new role of mutant proteins in some of the deadliest cancers

Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they ...

Dual studies uncover complementary strategies to overcome resistance to KRAS G12C inhibitors in lung cancer

Two companion studies published in Cancer Research by scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C-mutant non-small ...
Medscape

When in the Treatment Sequence Should Metastatic CRC Be Retreated With an Anti-EGFR?

Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...
ascopubs.org

p53 and K-ras Gene Mutations Correlate With Tumor Aggressiveness But Are Not of Routine Prognostic Value in Colorectal Cancer

Analysis of the p53/BAX Pathway in Colorectal Cancer: Low BAX Is a Negative Prognostic Factor in Patients With Resected Liver Metastases PATIENTS AND METHODS: One hundred forty patients were analyzed.
JSTOR Daily

Frequency and Spectrum of Mutations at Codons 12 and 13 of the C-K-ras Gene in Human Tumors

This is a preview. Log in through your library . Abstract The frequency of point mutations at codons 12 and 13 of the c-K-ras gene has been determined in a panel of more than 400 human tumors. Mutant ...
BioTechniques

RAS gene mutations fuel malignancy through crosstalk with tumor microenvironment

A single oncogenic mutation can hijack mechanisms causing benign tumors to become malignant. A study by researchers at Rockefeller University (NY, USA) finds that a single mutated gene in cancer stem ...
GEN

Health Canada Clears DxS’ K-RAS Mutation Kit as Test for Anti-EGFR Therapies

It can assess patients’ suitability for Amgen’s colorectal cancer drug, Vectibix. Canadian regulatory authorities approved DxS’ TheraScreen K-RAS Mutation Kit for use as a diagnostic for anti-EGFR ...